Safety profile-ATTR-CM

Safety

AMVUTTRA® has an established safety and tolerability profile in adults1

The safety and tolerability of AMVUTTRA were established in a study of adult patients with hATTR-PN (HELIOS-A).1

No new safety issues were identified in HELIOS-B. The frequency of pain in extremity, arthralgia, and dyspnea were similar to placebo.2

Safety in HELIOS-A (hATTR-PN)1

Chart showing the safety and tolerability profile during the HELIOS A clinical trialChart showing the safety and tolerability profile during the HELIOS A clinical trial

Safety in HELIOS-B (ATTR-CM)2

Chart showing the safety and tolerability profile during the HELIOS B clinical trialChart showing the safety and tolerability profile during the HELIOS B clinical trial

*Comprised of several similar terms.1

†Percentage only reflects those reported as an adverse reaction.1

No new safety concerns have been identified to date related to long-term reduction in TTR levels from Alnylam’s clinical studies, open-label extension studies, or post-marketing surveillance.2-6‡

*Comprised of several similar terms.1

†Percentage only reflects those reported as an adverse reaction.1

‡As of December 2025.

Stay informed

Receive more information about AMVUTTRA.

Connect with us

Starting treatment

Get your patients started on AMVUTTRA.

Up next: Learn About Dosing & Administration

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
  • polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

References

  1. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  2. Data on file. Alnylam Pharmaceuticals, Inc.
  3. Adams et al. Amyloid. 2023;30(1):18-26.
  4. Adams et al. JAMA Neurol. 2025;82(3):228-236.
  5. Fontana et al. N Engl J Med. 2025;392(1):33-44.
  6. Fontana et al. N Engl J Med. 2025;392(1):33-44 (supplement).
Alnylam Pharmaceuticals logo, click to visit corporate website

AMVUTTRA, Alnylam Assist, and their associated logos are trademarks of Alnylam Pharmaceuticals, Inc.

© 2026 Alnylam Pharmaceuticals, Inc. All rights reserved. This site is intended for US healthcare professionals. AMV-USA-00925